Expectations trend
FY2027 · fiscal year ending 2027-12-31 · fmp
Sana Biotechnology, Inc. (SANA)
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
$2.34-8.59%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for SANA yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
Manage cash flow and reduce operating expenses | Management is focused on improving cash flow and cutting expenses despite recent losses. | Intact | Cash from operating activities remains below -$30M per quarter beyond 2026 | Cash from operations: $-32.79M FY2026-Q2; GAAP. Published target: Reduce negative cash from operations to less than -$30M per quarter by end 2026. Annual target cannot be compared with a quarterly or TTM observation. Aug 10, 2026-32,790,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
FY2027 · fiscal year ending 2027-12-31 · fmp
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk, loss-making clinical-stage biotech with a speculative growth profile. The long-term thesis is in a watch state: management is progressing its stated priorities, but recent financial performance is weak and below its industry cohort.
The snapshot provides no valuation comparison or specific evidence about market expectations, so whether SANA is cheap, fair, or expensive versus peers cannot be assessed. Fragility is rated low, but that does not resolve the uncertainty around the company’s loss-making business or clinical progress.
Near term, ongoing investment in SC451 and SG293 is likely to keep losses in focus; the quarterly net loss rose while cash also increased, and cash runway is expected into mid-2027. Management says the trials are on track and operating cash burn for the first half of 2026 was lower than a year earlier, but the risk label recently rose to high.
Over the multi-year view, the key test is whether SC451 and SG293 advance through the planned clinical steps while cash and operating expenses remain manageable. Near-term guidance cuts or a weaker jobs trend are flagged as unfavorable, while continued strong results and guidance from major healthcare companies could support sector momentum.
SANA’s 1-3 year thesis remains uncertain: clinical execution and cash management are progressing, but losses, weak relative performance, and high risk leave little room for confidence. The evidence snapshot offers limited valuation detail. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 2 of 2 supplied quarters. Management reported: “Non-GAAP Measures • Non-GAAP Operating Cash Burn: Non-GAAP operating cash burn for the six months ended June 30, 2026 was $69.3 million compared to $79.0 million for the same period in 2025.” “Second Quarter 2026 Financial Results GAAP Results • Cash Position : Cash, cash equivalents, and marketable securities as of June 30, 2026 were $160.5 million compared to $138.4 million as of December 31, 2025.”
Delivery assessment Nov 4, 2026Advance SC451 and SG293 clinical trials | Sana is advancing key clinical trials for SC451 and SG293, aiming for important data points. | Intact | No significant progress or data release on SC451 and SG293 trials by end of 2026 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “Sana expects to file an IND and begin a Phase 1/2 clinical trial for SC451 as early as this year.” “Sana expects to generate first-in-human data for SG293 in non-Hodgkin lymphoma as early as this year.” Delivery assessment Nov 4, 2026 |
Leverage strategic partnership with Mayo Clinic | The company formed a strategic partnership with Mayo Clinic to boost research. | Improving | No measurable progress or collaboration outcomes from Mayo Clinic partnership by mid-2027 | Qualitative condition This condition has no defined numerical measure. Nov 4, 2026Last status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. Management contextStated in 2 of 2 supplied quarters. Management reported: “• In connection with the collaboration, Mayo Clinic made a $25.0 million equity investment in the company, reflecting a shared commitment to advancing innovative approaches aimed at improving care for patients with type 1 diabetes.” “• The purpose of the collaboration is to draw on Mayo Clinic’s multidisciplinary expertise to accelerate the development, validation, and standardization of protocols and processes for SC451, supporting safe, scalable, and consistent delivery across diverse clinical environments.” Delivery assessment Nov 4, 2026 |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
$-0.58 → $-0.59 · observed estimates
$0.01B → $0.01B · observed estimates
One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.
| Snapshot | EPS | Revenue | EPS / revenue analysts |
|---|---|---|---|
| 2026-07-24 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-07-25 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-07-26 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-07-27 | $-0.52 | $0 | 4 / 6 |
| 2026-07-28 | $-0.52 | $0 | 4 / 6 |
| 2026-07-29 | $-0.52 | $0 | 4 / 6 |
| 2026-07-30 | $-0.52 | $0 | 4 / 6 |
| 2026-07-31 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-01 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-02 | $-0.52 | $0 | 4 / 6 |
| 2026-08-03 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-04 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-05 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-06 | $-0.52 | $0 | 4 / 6 |
| 2026-08-08 | $-0.52 | $0 | 4 / 6 |
| 2026-08-09 | $-0.52 | $0 | 4 / 6 |
| 2026-08-10 | $-0.52 | $0 | 4 / 6 |
| 2026-08-12 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-13 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-14 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-15 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-16 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-17 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-18 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-19 | $-0.58 | $6,950,000 | 5 / 6 |
| 2026-08-20 | $-0.59 | $6,950,000 | 5 / 6 |
| 2026-08-21 | $-0.59 | $6,950,000 | 5 / 6 |
| 2026-08-22 | $-0.59 | $6,950,000 | 5 / 6 |
| 2026-08-23 | $-0.59 | $6,950,000 | 5 / 6 |
| 2026-08-24 | $-0.59 | $6,950,000 | 5 / 6 |
| 2026-08-25 | $-0.59 | $6,950,000 | 5 / 6 |
| 2026-08-26 | $-0.59 | $6,950,000 | 5 / 6 |
| 2026-08-27 | $-0.59 | $6,950,000 | 5 / 6 |
| 2026-08-28 | $-0.59 | $6,950,000 | 5 / 6 |
| 2026-08-29 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-08-30 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-08-31 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-01 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-02 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-03 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-04 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-05 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-06 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-07 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-08 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-09 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-10 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-11 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-12 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-13 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-14 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-15 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-16 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-17 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-18 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-19 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-20 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-21 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-22 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-23 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-24 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-25 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-26 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-27 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-28 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-29 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-09-30 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-01 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-02 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-03 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-04 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-05 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-06 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-07 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-08 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-09 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-10 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-11 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-12 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-13 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-14 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-15 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-16 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-17 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-18 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-19 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-20 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-21 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-22 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-23 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-24 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-25 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-26 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-27 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-28 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-29 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-30 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-10-31 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-11-01 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-11-02 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-11-03 | $-0.59 | $6,950,000 | 6 / 6 |
| 2026-11-04 | $-0.59 | $6,950,000 | 6 / 6 |
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Latest: 8 Buy / Strong Buy · 1 Hold · 0 Sell / Strong Sell
Recent actions · Oct 6–Nov 4 · 0 recorded
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.